A Phase 2/3 interventional study of PEG-Intron and Interferon Alfa-2B in Hepatitis C, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-09.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing peginterferon alfa-2b in Hepatitis C — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C.
Among the 23 studies testing peginterferon alfa-2b in Hepatitis C, this one is the 3rd largest by enrollment, is the only one that started in 1997, is one of 2 in phase 2/3, and was the 23rd registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 23 studies testing peginterferon alfa-2b in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 9 · Phase 4 6
First in 1997; this study’s year is marked. 1 started in 1997.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,224 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 102 across the 23 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
92 studies in Hepatitis C by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 86 finished, 66 (77%) have results posted.
Among the 92 studies in Hepatitis C by Merck & Co., Inc, this one has the largest enrollment of the 69 interventional ones that give a count, is the only one that started in 1997, is one of 3 in phase 2/3, and was the 92nd registered.
Merck & Co., Inc’s Hepatitis C studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing peginterferon alfa-2b in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 92 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will determine the efficacy of PEG-Intron (SCH 54031) in participants with chronic Hepatitis C virus (HCV) infection who have not been previously treated with interferon. Participants are randomized to receive one of three doses of PEG-Intron (0.5, 1.0, and 1.5 mg/kg) or Interferon Alfa-2B for 48 weeks. The primary objective of this study is to evaluate the efficacy of PEG-Intron (compared to Interferon Alfa-2B) with respect to response based on loss of detectable HCV ribonucleic acid (HCV-RNA) and normalization of alanine transaminase (ALT) level after 24 weeks of therapy and at 24 weeks of follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PEG-Intron administered once weekly (QW) for 48 weeks at 0.5 mg/kg by subcutaneous (SC) injection.
Biological: PEG-Intron
PEG-Intron administered QW for 48 weeks at 1.0 mg/kg by SC injection.
Biological: PEG-Intron
PEG-Intron administered QW for 48 weeks at 1.5 mg/kg by SC injection.
Biological: PEG-Intron
Interferon Alfa-2b administered three times per week (TIW) for 48 weeks at 3 million international units (MIU) by SC injection.
Biological: Interferon Alfa-2B
PEG-Intron is administered QW for 48 weeks by SC injection at 0.5, 1.0, and 1.5 mg/kg body weight. Body weight obtained at the baseline visit is used to calculate dosing.
Also known as: SCH 54031
Interferon alfa-2b is administered TIW for 48 weeks by SC injection at 3 MIU regardless of participant body weight.
Number of Participants Achieving Responder Status at 24 Weeks of Treatment
The number of participants achieving responder status at 24 weeks of treatment was assessed. A participant was classified as a responder if, at 24 weeks of treatment, they met both of the following criteria: 1) HCV-Ribonucleic Acid (RNA) negative (defined as \<100 copies/mL serum by quantitative polymerase chain reaction \[qPCR\] assay); and 2) alanine transaminase (ALT) level normal.
Time frame: Up to 24 weeks
Number of Participants Achieving Sustained Responder Status at 24 Weeks of Follow-up
The number of participants achieving sustained responder status at 24 weeks of follow-up was assessed. A participant was classified as a sustained responder if, at 24 weeks of follow-up, they met both of the following criteria: 1) HCV-RNA negative (defined as \<100 copies/mL serum by qPCR assay); and 2) ALT level normal.
Time frame: Up to 72 weeks (up to 48 weeks treatment and 24 weeks follow-up)
In total, 1224 participants with chronic Hepatitis C virus (HCV) infection were randomized, with 1219 receiving study treatment.
| Milestone | PEG-Intron, 0.5 mg/kg | PEG-Intron, 1.0 mg/kg | PEG-Intron, 1.5 mg/kg | Interferon Alfa-2b |
|---|---|---|---|---|
| Started | 315 | 298 | 304 | 307 |
| Treated | 315 | 297 | 304 | 303 |
| Completed | 255 | 229 | 228 | 231 |
| Not completed | 60 | 69 | 76 | 76 |
The number of participants achieving responder status at 24 weeks of treatment was assessed. A participant was classified as a responder if, at 24 weeks of treatment, they met both of the following criteria: 1) HCV-Ribonucleic Acid (RNA) negative (defined as \<100 copies/mL serum by quantitative polymerase chain reaction \[qPCR\] assay); and 2) alanine transaminase (ALT) level normal.
| Participants | PEG-Intron, 0.5 mg/kg | PEG-Intron, 1.0 mg/kg | PEG-Intron, 1.5 mg/kg | Interferon Alfa-2b |
|---|---|---|---|---|
| Number of Participants Achieving Responder Status at 24 Weeks of Treatment | 80 | 87 | 90 | 59 |
The number of participants achieving sustained responder status at 24 weeks of follow-up was assessed. A participant was classified as a sustained responder if, at 24 weeks of follow-up, they met both of the following criteria: 1) HCV-RNA negative (defined as \<100 copies/mL serum by qPCR assay); and 2) ALT level normal.
| Participants | PEG-Intron, 0.5 mg/kg | PEG-Intron, 1.0 mg/kg | PEG-Intron, 1.5 mg/kg | Interferon Alfa-2b |
|---|---|---|---|---|
| Number of Participants Achieving Sustained Responder Status at 24 Weeks of Follow-up | 52 | 70 | 69 | 37 |
Collected over Up to 72 weeks (up to 48 weeks treatment and 24 weeks of follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PEG-Intron, 0.5 mg/kg | 1/315 (0.3%) | 37/315 (11.7%) | 306/315 (97.1%) |
| PEG-Intron, 1.0 mg/kg | 0/297 (0%) | 32/297 (10.8%) | 291/297 (98%) |
| PEG-Intron, 1.5 mg/kg | 0/304 (0%) | 31/304 (10.2%) | 296/304 (97.4%) |
| Interferon Alfa-2b | 2/303 (0.7%) | 29/303 (9.6%) | 293/303 (96.7%) |
| Event | PEG-Intron, 0.5 mg/kg | PEG-Intron, 1.0 mg/kg | PEG-Intron, 1.5 mg/kg | Interferon Alfa-2b |
|---|---|---|---|---|
| Facial paralysisNervous system disorders | 1/315 | 3/297 | 0/304 | 0/303 |
| Suicidal ideationPsychiatric disorders | 3/315 | 2/297 | 2/304 | 1/303 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/315 | 2/297 | 0/304 | 0/303 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/315 | 2/297 | 0/304 | 0/303 |
| Musculoskeletal disorderMusculoskeletal and connective tissue disorders | 0/315 | 0/297 | 0/304 | 2/303 |
| VertigoEar and labyrinth disorders | 0/315 | 0/297 | 2/304 | 0/303 |
| PneumoniaInfections and infestations | 0/315 | 1/297 | 2/304 | 0/303 |
| Suicide attemptPsychiatric disorders | 0/315 | 0/297 | 2/304 | 0/303 |
| HypertensionVascular disorders | 0/315 | 0/297 | 2/304 | 0/303 |
| Spinal disorderMusculoskeletal and connective tissue disorders | 0/315 | 1/297 | 2/304 | 0/303 |
| Event | PEG-Intron, 0.5 mg/kg | PEG-Intron, 1.0 mg/kg | PEG-Intron, 1.5 mg/kg | Interferon Alfa-2b |
|---|---|---|---|---|
| HeadacheNervous system disorders | 192/315 | 200/297 | 195/304 | 177/303 |
| FatigueGeneral disorders | 160/315 | 164/297 | 159/304 | 170/303 |
| MyalgiaMusculoskeletal and connective tissue disorders | 111/315 | 107/297 | 135/304 | 114/303 |
| ChillsGeneral disorders | 106/315 | 120/297 | 133/304 | 99/303 |
| Injection site erythemaGeneral disorders | 135/315 | 120/297 | 122/304 | 47/303 |
| PyrexiaGeneral disorders | 96/315 | 124/297 | 127/304 | 86/303 |
| AlopeciaSkin and subcutaneous tissue disorders | 64/315 | 68/297 | 104/304 | 67/303 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 78/315 | 71/297 | 86/304 | 73/303 |
| NauseaGastrointestinal disorders | 73/315 | 83/297 | 83/304 | 64/303 |
| Influenza like illnessGeneral disorders | 57/315 | 66/297 | 76/304 | 59/303 |
Includes all randomized participants receiving ≥1 dose of study treatment.
| Age, Continuous(Years) | PEG-Intron, 0.5 mg/kg | PEG-Intron, 1.0 mg/kg | PEG-Intron, 1.5 mg/kg | Interferon Alfa-2b | Total |
|---|---|---|---|---|---|
| Mean | 43.1 ± 9.4 | 43.7 ± 9.5 | 42.9 ± 8.7 | 42.6 ± 9.2 | 43.1 ± 9.2 |
| Sex: Female, Male(Participants) | PEG-Intron, 0.5 mg/kg | PEG-Intron, 1.0 mg/kg | PEG-Intron, 1.5 mg/kg | Interferon Alfa-2b | Total |
|---|---|---|---|---|---|
| Female | 130 | 109 | 114 | 96 | 449 |
| Male | 185 | 188 | 190 | 207 | 770 |
No study locations are listed for this record.
Ran from Aug 1997 to primary completion in Jul 1999, 23 months.
Results were first posted in Apr 2019, 19 years 8 months after primary completion.
Of 14 phase 2/3 interventional studies under Hepatitis C, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 51. This study's 23 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2b